Table 1.
Characteristics of 713 Participants in the SCOLTA Dolutegravir Cohort, According to Antiretroviral Regimen
| Total | 3TC+DTG | RPV+DTG | PI+DTG | 3TC/ABC/DTG | TDF/FTC+DTG | TAF/FTC+DTG | ||
|---|---|---|---|---|---|---|---|---|
| n = 713 | n = 75 | n = 45 | n = 60 | n = 326 | n = 148 | n = 59 | P | |
| Sex M, No. (%) | 533 (74.7) | 59 (78.7) | 26 (57.8) | 45 (75.0) | 244 (74.8) | 111 (75.0) | 48 (81.4) | .12 |
| Age, mean ± SD, y | 47.2 ± 11.6 | 50.6 ± 11.1 | 51.8 ± 10.8 | 50.4 ± 11.3 | 46.9 ± 11.5 | 45.0 ± 11.2 | 43.8 ± 12.4 | <.0001 |
| Caucasian, No. (%) | 648 (90.9) | 69 (92.0) | 43 (95.6) | 55 (91.7) | 294 (90.2) | 139 (93.9) | 48 (81.4) | .09 |
| Weight, mean ± SD, kg | 70.5 ± 13.4 | 73.3 ± 13.9 | 70.2 ± 13.3 | 70.4 ± 11.5 | 69.8 ± 13.1 | 70.6 ± 14.6 | 71.4 ± 13.0 | .46 |
| BMI (n = 608), mean ± SD, kg/m2 | 24.2 ± 4.0 | 24.5 ± 3.5 | 25.0 ± 3.8 | 24.2 ± 3.5 | 24.0 ± 4.0 | 24.0 ± 4.2 | 24.7 ± 4.3 | .61 |
| Risk factor for HIV acquisition, No. (%) | ||||||||
| Sexual | 513 (72.0) | 59 (78.7) | 33 (73.3) | 39 (65.0) | 245 (75.2) | 85 (57.4) | 52 (88.1) | |
| IVDU | 112 (15.7) | 8 (10.7) | 11 (24.2) | 14 (23.3) | 42 (12.8) | 32 (21.6) | 5 (8.5) | <.0001 |
| Other | 88 (12.3) | 8 (10.7) | 1 (2.2) | 7 (11.7) | 39 (12.0) | 31 (21.0) | 2 (3.4) | |
| CD4, mean ± SD, cells/mL | 570 ± 367 | 725 ± 422 | 699 ± 318 | 614 ± 317 | 617 ± 359 | 419 ± 330 | 364 ± 312 | <.0001 |
| CD4/CD8 (n = 616), median (IQR) | 0.64 (0.34–0.99) | 0.90 (0.57–1.23) | 0.92 (0.62–1.14) | 0.67 (0.50–0.97) | 0.68 (0.41–1.03) | 0.44 (0.17–0.74) | 0.38 (0.11–0.67) | <.0001 |
| Naïve, No. (%) | 195 (27.4) | 5 (6.7) | 1 (2.2) | 1 (1.7) | 75 (23.0) | 68 (45.9) | 45 (76.3) | <.0001 |
| CDC stage C, No. (%) | 159 (22.3) | 10 (13.3) | 9 (20.0) | 20 (33.3) | 69 (21.2) | 38 (25.7) | 13 (22.0) | .07 |
| HIV-RNA >50 copies/mL (experienced participants), No. (%) | 95 (18.3) | 6 (8.6) | 1 (2.3) | 22 (37.3) | 39 (15.5) | 24 (30.0) | 3 (21.4) | <.0001 |
| Years of ART (experienced participants), median (IQR) | 9.8 (4.3–17.4) | 10.8 (7.5–17.6) | 12.1 (6.7–18.3) | 13.5 (6.8–19.2) | 7.9 (4.0–15.5) | 9.2 (3.2–17.3) | 9.1 (4.5–19.0) | .004 |
| HCV active infection (baseline), No. (%) | 66 (9.3) | 2 (2.7) | 2 (4.4) | 7 (11.7) | 27 (8.3) | 25 (16.9) | 3 (5.1) | .004 |
| HCV eradication during follow-up (n = 66), No. (%) | 30 (45.4) | 0 (0) | 1 (50.0) | 3 (42.9) | 15 (55.6) | 10 (40.0) | 1 (33.3) | .66 |
| Statin use at baseline, No. (%) | 65 (9.1) | 11 (14.7) | 7 (15.6) | 9 (15.0) | 26 (8.0) | 9 (6.1) | 3 (5.1) | .05 |
| Statin started during the first year of observation (n = 648), No. (%) | 17 (2.6) | 2 (3.1) | 3 (7.9) | 2 (3.9) | 6 (2.0) | 3 (2.2) | 1 (1.8) | .38 |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BMI, body mass index; CDC, Centers for Disease Control and Prevention; DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; IQR, interquartile range; IVDU, intravenous drug use; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); SCOLTA, Surveillance Cohort Long-Term Toxicity Antiretrovirals; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.